Drug intelligence / Profile preview

KT-20610

Development stage: Unknown
Lead developer: Kingdom Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

KT-20610 is a novel topical antifungal agent currently under development by Kaken Pharmaceutical for the treatment of onychomycosis (fungal nail infection). While specific structural details are proprietary, it is designed to penetrate the nail plate effectively to reach the site of infection. The drug is currently in Phase 2 clinical trials in Japan, aiming to provide a new therapeutic option for patients with fungal nail infections, a market where Kaken previously established a presence with efinaconazole (Jublia).

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on KT-20610.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KT-20610.

Explore the full profile